Terminally wounded Boehringer retires from hepatitis C race
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has formally withdrawn from the hepatitis C space. It says it will pull all pending marketing applications worldwide for its drug candidate faldaprevir, and discontinue further development.